SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (573)6/19/1999 3:50:00 PM
From: Jongmans   of 4474
 
Mike,

In my view, the osteoporosis program is not a part of the joint venture. The 50/50 is only for new potential products developed within the joint venture. See press-release ARIAD/HMR dd march 6,1997
which states: Operating costs of the joint venture and the right to candidate therapeutic proteins and drug targets will be divided equally between Hoechst Marion Roussel and ARIAD etc:

corporate-ir.net

For Osteoporosis-collaboration see press-release dd November 7 1995.

best regards

Martin
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News